Call for Abstract

10th International Conference on Cancer & Tumor Immunology, will be organized around the theme ““Explore the Possibilities in the Field of Cancer and Tumor””

Cancer Immunology 2017 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Cancer Immunology 2017

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

Cancer immunology will outline the basic biology of immune responses with the goal of developing new immune therapy approaches and improving existing ones. Basic research to investigate, at the cellular and molecular levels, the mechanisms that regulate the immune system, yielding knowledge that will further our efforts to harness the power of the immune system to treat cancer.

  • Track 1-1 Thyroid Cancer
  • Track 1-2Vaginal Cancer
  • Track 1-3Penile Cancer
  • Track 1-4 Adrenal Cancer
  • Track 1-5Gall Bladder Cancer
  • Track 1-6Tubal Cancer
  • Track 1-7Gastric Cancer
  • Track 1-8Tonsil Cancer
  • Track 1-9Testicular Cancer
  • Track 1-10Spinal Cancer
  • Track 1-11Renal Cancer
  • Track 1-12Esophageal Cancer
  • Track 1-13Molecular & cellular oncology
  • Track 1-14Bone Cancer
  • Track 1-15 Colorectal cancer
  • Track 1-16Brain Cancer
  • Track 1-17Breast Cancer
  • Track 1-18 Skin Cancer
  • Track 1-19 Cervical Cancer
  • Track 1-20Liver Cancer
  • Track 1-21Pancreatic Cancer
  • Track 1-22Prostate Cancer
  • Track 1-23Uterine Cancer
  • Track 1-24Immune modulation of tumors
  • Track 1-25Bladder Cancer

Tumor Immunology determining the function and behavior of innate and adaptive immune cells in health and disease, including the interactions with their microenvironment. Understanding the basic principles underlying immune cell development, activation, regulation, differentiation and death as well as the molecular mechanisms underlying diversity and plasticity of the immune system is a prerequisite for the design of targeted manipulation strategies to protect from cancer, autoimmunity and infection and to foster and devise the development of novel therapeutic approaches. To address their research questions the individual groups develop and use sophisticated experimental model systems and technologies such as genetic barcoding, structural biology and high-throughput single cell analysis platforms.

  • Track 2-1 Tumor and its Classification
  • Track 2-2Immune modulation of Tumors

Covers all areas of immunology including cellular and molecular immunology, immunochemistry, immunogenetics, imaging, mathematical modelling, allergy, transplantation immunology, cancer immunology, clinical immunology and immunological therapies, physiological functioning of the immune system in states of both health and disease, malfunctions of the immune system in immunological disorders and therapies (autoimmune diseases, hypersensitivities, immune deficiency, transplant rejection), the physical, chemical and physiological characteristics of the components of the immune system in vitro, in situ, and in vivo are of prime interest.

  • Track 3-1Tumor Antigens
  • Track 3-2 Immune systems Stimulants
  • Track 3-3Newer Monoclonal Antibodies
  • Track 3-4Targeting Immunotherapy Cancer Treatment
  • Track 3-5sublingual immunotherapy

Prolonged inflammation can damage your body’s healthy cells and tissue, and weaken your immune system, The link between inflammation and cancers, cancers tended to occur at sites of chronic inflammation. Lately, it turned out that acute inflammation contributed to the regression of cancer. inflammation and innate immunity are important targets in patients with cancer

  • Track 4-1 Acute Inflammation
  • Track 4-2Chronic Inflammation

People with HIV/AIDS are at high risk for developing certain cancers, such as Kaposi's sarcoma, non-Hodgkin lymphoma, and cervical cancer. For people with HIV, these three cancers are often called "AIDS-defining conditions. Most types of cancer begin when normal cells begin to change and grow uncontrollably, forming a mass called a tumor. A tumor can be benign (noncancerous) or malignant (cancerous, meaning it can spread to other parts of the body).

  • Track 5-1HIV vaccines
  • Track 5-2New Theraputic Approaches

Cancers are not just masses of malignant cells but complex ‘rogue’ organs, to which many other cells are recruited and can be corrupted by the transformed cells. Interactions between malignant and non-transformed cells create the tumor microenvironment. Changes of the tumor microenvironment have been closely correlated to cancer-mediated inflammation. 

  • Track 6-1Targeting myloma with Microenvinorment
  • Track 6-2Characterstics of Micro envinorment

A cancer vaccine is a vaccine that treats with existing cancer or prevents development of a cancer. Cancer vaccines are also   known as biological response modifiers. A biological response modifier helps by stimulating or restoring the immune system’s ability to fight infections and disease. The most commonly used side effect of cancer vaccines is inflammation at the site of injection, including redness, pain, swelling, warming of the skin, itchiness, and occasionally a rash. Mainly these vaccines include cell therapy and gene therapy.

  • Track 7-1Cell Therapy
  • Track 7-2Gene Therapy
  • Track 7-3Metabolomic cancer therapy
  • Track 7-4Harmone therapies
  • Track 7-5Chemotherapy

Cancer prognosis gives us information about the percentage of people who survive a certain type of cancer for specific amount of time. Some of the factors that affect  prognosis like  type of cancer, its location in the body,  stage, size of the cancer,  cancer’s grade and age of the patients etc… The time of period varies; it may be 1 year, 2 years, 5 years, and etc... Cancer-specific survival is also called as Disease-specific survival. There are different ways to measure and report survival and statistics of cancer. This cancer prognosis that mainly include liver cancer prognosis, metastatic prognosis and brain cancer prognosis

  • Track 8-1Liver cancer Prognosis
  • Track 8-2Metastaic Prognosis
  • Track 8-3Brain Cancer Prognosis

Cancer cell biology can be defined as a disease of the genes. This is the small part of DNA and master molecule of the cell. The main two characteristics are uncontrolled growth of the cells in the human body and the ability of these cells to migrate and spread to distant sites. If the spread is not controlled, cancer can result in death. Bone marrow stromal stem cells also called mesenchyme stem cells or skeletal stem cells and these can generate bone, cartilage, and fat cells. The cancer pathology is a medical document that written by a pathologist. A pathologist is a doctor who specializes in interpreting laboratory tests and evaluating cells, tissues, and organs to diagnose disease.

  • Track 9-1clinical oncology
  • Track 9-2Surgical Oncology
  • Track 9-3Cancer Stem Cells
  • Track 9-4Cancer Pathology

 Cells may acquire mutations in genes that control proliferation, such as tumor suppressor genes. Tumors grow in a series of steps. The first step is hyperplasia, resulting from uncontrolled cell division. These cells appear normal, but some changes occurred that results in loss of control of growth. The second step is dysplasia, resulting from further growth, accompanied by abnormal changes to the cells. The third step requires additional changes, which result in cells that are even more abnormal and can now spread over a wider area of tissue. These cells begin to lose their original function; such cells are called anaplastic. At this stage, the tumors  is still contained within its original location (called in situ) and is not invasive, it is not considered malignant - it is potentially malignant. The last step occurs when the cells in the tumor metastasize, which means that they can invade surrounding tissue, including the bloodstream, and spread to other locations. This is the most serious type of tumor, but not all tumors progress to this point. These Tumor Biology that mainly Include Molecular and Cellular oncology and Immuno oncology.

  • Track 10-1cellular pathology
  • Track 10-2Extragonadal Germ Cell Tumors
  • Track 10-3Benign tumor
  • Track 10-4Malignent Tumor
  • Track 10-5Brain Tumor
  • Track 10-6Tumor molecular profiling
  • Track 10-7Genomic tumor assessment
  • Track 10-8Immuno-Oncology
  • Track 10-9Molecular & cellular oncology
  • Track 10-10Islet Cell Tumor
  • Track 10-11Ovarian Germ Cell Tumors

Cancer care costs are a financial burden to patients, their families, and society as a whole. In 2006 medical expenses from cancer care in the United States were an estimated $104.1 billion. Cancer can be a major cause of lack of money. This may be due either to the costs of treating and managing the illness as well as its impact upon people's ability to work. This particularly affects countries that lack comprehensive social health insurance systems and other types of social safety nets. The study is a longitudinal short study of 10,000 hospital patients with a first time diagnosis of cancer. Patients were assigned a socioeconomic status according to the district of residence at diagnosis. Continuity of patients due to cancer living in the most deprived district was compared to survival of patients living in all other districts by model-based period analysis. These major regional socioeconomic inequalities indicate a potential for improving cancer care and survival in Germany. Studies on individual patient data with access to treatment information should be conducted to examine the reasons for these socioeconomic inequalities in cancer survival in more detail.

  • Track 11-1Distribution of economic impact
  • Track 11-2Estimation of direct and indirect cost of cancer
  • Track 11-3Socio economic disparities in cancer burden
  • Track 11-4 Anticancer drugs in global market: economy and their cost effectiveness

The goal of the Cancer Research Program is to make significant improvements in the prevention, early detection, diagnosis and treatment of cancer. Research into the cause of cancer involves many different disciplines including genetics, diet, environmental factors (i.e. chemical carcinogens).  And it will continue to translate basic research findings into clinical applications together with strategic partners, with the National Centre for Tumor Diseases (NCT) and the nationally active German Consortium for Translational Cancer Research (DKTK) playing key roles. The program is also developing new approaches in the fields of cancer genome and epigenome research, metabolic dysfunction, personalized radiation oncology and ion therapy, molecular imaging, neuro-oncology, individualized cancer medicine and health economics.

  • Track 12-1Radiation oncology research
  • Track 12-2Cancer Immunology Research
  • Track 12-3 Clinical Cancer Research
  • Track 12-4Molecular Cancer Research
  • Track 12-5Molecular Cancer Therapeutics
  • Track 12-6Cancer Prevention Research

Immuno-oncology therapies activate our immune system, making it able to recognise cancer cells and destroy them. Breast cancer is one of the major cancer types for which new immune-based cancer treatments are currently in development. Lung cancer surgery carries risks, including bleeding and infection. Clinical trials are studies of experimental lung cancer treatments. The immune system is the body’s natural defence system. It is a collection of organs, cells and special molecules that helps protect you from infections, cancer and other diseases. Adult central nervous system tumor is a disease in which abnormal cells form in the tissues of the brain and/or spinal cord. A tumor that starts in another part of the body and spreads to the brain is called a metastatic brain tumor. There are different types of brain and spinal cord tumors such as Astrocytic Tumors, Oligodendroglia Tumors, Mixed Gliomas, Ependymal Tumors, Medulloblastomas, Pineal Parenchymal Tumors, Meningeal Tumors, Germ Cell Tumors and Craniopharyngiom. Advances in Immuno-oncology have given oncologists and their patients reason to be encouraged—the launch of immune checkpoint inhibitors and development of other immunotherapy assets for the treatment of several difficult-to-treat diseases, including metastatic melanoma and non-small cell lung cancer, represents great progress.

  • Track 13-1Gastrointestinal
  • Track 13-2Genitourinary
  • Track 13-3Melanoma

The epidermal growth factor receptor (EGFR) autocrine pathway contributes to a number of processes important to cancer development and progression, including cell proliferation, apoptosis, and angiogenesis. Immunotherapy encompasses several different treatment approaches, each of which has a distinct mechanism of action, and all of which are designed to boost or restore immune function in some manner.  This includes: Monoclonal antibodies, Immune checkpoint inhibitors, Therapeutic Cancer vaccines, cytokines, and other non-specific immunotherapies. And mainly includes Metabolomics in Novel Biomarker Discovery.

  • Track 14-1Molecular Cancer Therapeutics
  • Track 14-2Metabolomics in Novel Biomarker Discovery